RTGN Share Price Performance
Recent RTGN News & Updates
No updates
RetinalGenix Technologies Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.15
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -33.3%
RetinalGenix Technologies Inc. Competitors
About RTGN
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer’s syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
U.S. Market Performance
- 7 Days: -0.3%
- 3 Months: 14.2%
- 1 Year: 15.7%
- Year to Date: 8.0%
In the last week, the market has stayed flat, however the Energy sector stood out, gaining 3.9%. Meanwhile, the market is actually up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading